Replimune is a clinical-stage biotechnology company with zero product revenue, investing heavily to advance its oncolytic virus candidate RP1 through pivotal trials.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 28, 2026 | -$0.54+31.1% vs -$0.78 | — vs $1M |
Q3 2026 Aug 14, 2026 | -$0.72-3.7% vs -$0.69 | — vs $14M |
Q3 2026 Jun 29, 2026 | -$0.76-4.1% vs -$0.73 | — vs $4M |
Q1 2026 Feb 3, 2026 | -$0.77-0.2% vs -$0.77 | — vs $428,571 |
The mean of analysts' price targets for Replimune Group (REPL) points to a 26.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Replimune ended the second quarter with $307.8 million in cash. Over 15 institutions wrote prescriptions within 20 business days.
Replimune Group, Inc. ( REPL ) Q2 2027 Earnings Call October 28, 2026 8:00 AM EDT Company Participants Arleen Goldenberg Sushil Patel - CEO & Director Michelle DiNapoli - Chief Commercial Officer Emily Hill - Chief Financial Officer Conference Call Participants Evan Seigerman - BMO Capital Markets Equity Research Allison Bratzel - Piper Sandler & Co., Research Division Anupam Rama - JPMorgan Chase & Co, Research Division Jiale Song - Jefferies LLC, Research Division Mubeen Mosaheb Romy O'Connor - Van Lanschot Kempen NV Presentation Operator Good day, and thank you for standing by. Welcome to the Replimune's Second Quarter Fiscal 2027 Earnings Conference Call.
TUDRIQEV first delivered to patients for advanced melanoma on October 6th More than 15 institutions have prescribed TUDRIQEV Management will host a webcast today at 8:00 a.m. ET WOBURN, Mass.
Benchmark REPL against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Replimune Group, Inc. (REPL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $21.62 | $1.82B | -8.39 | — | — | -157.78% | — | |
| $460.42 | $248.49B | 26.77 | 9.92% | 24.12% | 85.59% | 2.05% | |
| $30.53 | $6.3B | -11.66 | — | -7585.86% | -69.59% | — | |
| $1.96 | $185.32M | 5.27 | 161.14% | 47.55% | 42.57% | — | |
| $8.04 | $3.59B | -16.62 | 60.6% | -58.19% | -29.71% | — | |
| $37.26 | $1.23B | -7.84 | -43.89% | -287.84% | -37.99% | — |
Replimune Group, Inc. (REPL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Replimune Group, Inc. (REPL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 14, 2026·SEC
Aug 10, 2026·SEC
Aug 7, 2026·SEC
Get notified when REPL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Replimune Group, Inc. (REPL) stock FAQ — growth, dividends, profitability & financials explained
No. Replimune Group, Inc. (REPL) reported a net loss of $271.0M over the trailing twelve months.
Replimune Group, Inc. (REPL) had a return on equity (ROE) of -157.8% over the trailing twelve months. A negative ROE means the company lost money over the period.
Replimune Group, Inc. (REPL) had negative free cash flow of $245.8M over the trailing twelve months.
